

(Rs. in Lakhs)

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2019

Particulars	Quarter ended			Nine months ended		Year ended
	31-12-2019	30-09-2019	31-12-2018	31-12-2019	31-12-2018	31-03-2019
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1 Revenue from Operations	9,437	9,849	9,097	28,690	26,136	33,016
2 Other Income	4	15	2	35	38	80
3 Total Income	9,441	9,864	9,099	28,725	26,174	33,096
4 Expenses						
(a) Cost of Materials Consumed	2,273	1,746	1,459	5,696	4,164	5,117
(b) Purchases of Stock-in-Trade	1,849	1,951	1,132	4,934	3,304	4,516
(c) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	(932)	(436)	336	(906)	1,212	1,371
(d) Employee Benefits Expense	2,417	2,493	2,394	7,222	7,002	8,993
(e) Finance Costs	36	36	99	145	308	399
(f) Depreciation and Amortisation Expense	416	416	386	1,224	1,138	1,532
(g) Other Expenses	2,341	2,454	2,568	7,079	7,753	9,663
Total Expenses	8,400	8,660	8,374	25,394	24,881	31,591
5 Profit before tax	1,041	1,204	725	3,331	1,293	1,505
6 Income tax expenses						
a. Current Tax	327	321	120	948	266	284
b. Deferred Tax	(77)	(94)	77	(220)	100	140
7 Profit for the period	791	977	528	2,603	927	1,081
8 Other Comprehensive Income						
(i) Items that will not be reclassified to Profit or Loss	(10)	(10)	(6)	(30)	(18)	(41)
(ii) Income tax relating to items that will not be reclassified to Profit or Loss	2	3	2	8	6	14
Other Comprehensive Income Net of Tax	(8)	(7)	(4)	(22)	(12)	(27)
9 Total Comprehensive Income for the period	783	970	524	2,581	915	1,054
10 Paid-up Equity Share Capital (Face Value Rs. 8 each)	1,323	1,323	1,323	1,323	1,323	1,323
11 Other Equity						14,727
12 Earnings per Share (of Rs. 8 each) (not annualised):						
(a) Basic	4.78	5.91	3.19	15.74	5.61	6.54
(b) Diluted	4.78	5.91	3.19	15.74	5.61	6.54

Notes:

- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on January 31, 2020. The Statutory Auditors of the Company have conducted a 'Limited Review' of the results for the quarter and nine months ended December 31, 2019.
- The Company operates in only one reportable business segment i.e., Pharmaceuticals.
- Effective April 1, 2019 the Company has adopted Ind AS 116 "Leases" using the modified retrospective approach. This has resulted in recognising right of use assets and lease liability as on April 1, 2019. The adoption of the standard did not have any material impact on the financial results.

For RPG Life Sciences Limited

Yugal Sikri
Managing Director
Mumbai, January 31, 2020